GLP-1 and Muscle Loss: How to Preserve Lean Mass While Losing Weight

What the Clinical Evidence Shows

The STEP 1 trial (Wilding et al., NEJM, 2021), the landmark study establishing semaglutide 2.4 mg for chronic weight management, showed participants losing an average of 14.9% of body weight over 68 weeks. That is a substantial result. However, when researchers examined body composition using DEXA scans, they found that roughly 25–40% of the total weight lost came from lean body mass — a proportion consistent with calorie-deficit weight loss in general.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022), which followed participants for two years, confirmed these findings over a longer horizon. The pattern held: significant fat mass reduction, with lean mass also declining in proportion.

More recently, Conte et al. (2024) published an analysis examining GLP-1-associated body composition changes across multiple cohorts. Their findings underscored that the rate of weight loss and protein adequacy were the two modifiable factors most strongly associated with lean mass preservation. Patients losing weight rapidly on insufficient dietary protein showed the greatest lean mass decline.

This is important context. GLP-1 medications suppress appetite significantly. Without deliberate attention to protein intake, it is easy — perhaps likely — that patients end up in a state of both caloric and protein deficit simultaneously.

Why Muscle Loss Matters Beyond Aesthetics

When people think about muscle loss during dieting, they often frame it as a cosmetic concern. It is far more than that.

Metabolic rate. Lean muscle tissue is metabolically active. Losing significant muscle mass lowers your resting metabolic rate, making weight regain more likely after treatment ends.

Functional strength and mobility. Muscle mass underpins balance, coordination, and the ability to perform daily activities. This is especially relevant for patients over 40, where age-related muscle loss (sarcopenia) is already an underlying risk.

Insulin sensitivity. Skeletal muscle is the primary site of glucose disposal after meals. Preserving muscle mass supports better glucose regulation — a priority for patients with prediabetes or type 2 diabetes.

Long-term weight maintenance. Patients with more preserved lean mass after weight loss consistently show better weight maintenance outcomes in follow-up studies.

The Three Pillars of Lean Mass Preservation on GLP-1

1. Protein — Non-Negotiable

The single most evidence-backed intervention for preserving lean mass during caloric restriction is adequate dietary protein. Current evidence suggests a target of 1.2–1.6 g of protein per kg of body weight per day during active weight loss — higher than typical population recommendations.

For someone weighing 80 kg, this means 96–128 g of protein daily. For patients on GLP-1 who are eating significantly less food overall, hitting this target requires intentional food choices at every meal.

Practical guidance:

• Prioritise protein at every meal before eating other foods. GLP-1 reduces meal size; what you eat first matters.
• Choose high-quality protein sources: eggs, poultry, fish, Greek yoghurt, cottage cheese, legumes combined with grains, or a well-formulated protein supplement.
• If appetite suppression makes food unappealing, liquid protein sources (shakes, soups) can help bridge the gap.

2. Resistance Training — The Anabolic Signal

Protein alone is not sufficient. The body also needs a signal to use that protein for muscle repair and synthesis. Resistance training — lifting weights, using resistance bands, or performing bodyweight exercises — is that signal.

Studies on older adults in caloric deficit consistently show that those who perform resistance training twice or more per week preserve significantly more lean mass than those who rely on dietary changes alone.

For GLP-1 patients, the recommendation is straightforward:

• Frequency: At least 2–3 sessions per week
• Focus: Compound movements that recruit large muscle groups (squats, hinges, rows, presses)
• Intensity: Progressive — increase resistance gradually as strength improves
• Accessibility: This does not require a gym. A set of resistance bands and a mat can form the basis of an effective programme at home.

The timing of training relative to protein intake also matters: consuming protein within 1–2 hours post-exercise supports muscle protein synthesis.

3. Rate of Weight Loss — Slower Is Often Smarter for Muscle

Rapid caloric restriction accelerates lean mass loss. While GLP-1 medications can produce fast results, deliberately moderating the rate of weight loss — especially in the early months — may preserve more muscle over the long term.

A target of 0.5–1% of body weight per week is often cited as a range that allows meaningful fat loss while limiting lean tissue degradation. Working with a clinician to adjust dosing titration or caloric intake targets with this in mind is reasonable, particularly for patients who are lean to begin with or who have existing concerns about muscle mass.

Supplements Worth Considering

Creatine monohydrate has the strongest evidence base among supplements for lean mass support. It does not build muscle independently, but it enhances the training response — improving strength, power output, and potentially muscle protein retention during caloric deficit. It is low-risk, well-tolerated, and inexpensive.

Leucine and essential amino acids (often delivered via branched-chain amino acid or essential amino acid supplements) may support muscle protein synthesis, particularly for those struggling to meet protein targets through food alone.

Vitamin D and omega-3 fatty acids have emerging evidence for muscle function, though they are not substitutes for protein and training.

What to Discuss with Your Care Team

If you are on GLP-1 therapy and concerned about muscle loss, these are productive questions to raise:

1. Should I have baseline DEXA or body composition testing so we can monitor lean mass over time?
2. What is my target protein intake given my current weight and pace of loss?
3. Are my current activity levels adequate, and is there a resistance training programme appropriate for my fitness level?
4. Is my rate of weight loss in a range that balances outcomes with lean mass preservation?

These are not unusual questions. A well-integrated weight management programme will address them proactively.

Key Takeaways

• GLP-1 medications like semaglutide do result in some lean mass loss, consistent with general weight loss physiology
• The STEP trials and Conte 2024 data confirm this, but also identify protein intake and physical activity as modifiable protective factors
• Eating sufficient protein (1.2–1.6 g/kg/day), performing resistance training 2–3x/week, and managing rate of loss are the three core strategies
• Muscle loss during weight loss is not inevitable — but it requires deliberate action, not passive hope

Frequently Asked Questions

Does semaglutide cause muscle loss? Semaglutide, like other forms of significant caloric restriction, is associated with some loss of lean body mass. Clinical trials show 25–40% of total weight lost may come from lean tissue, depending on protein intake and physical activity. This can be substantially reduced with adequate protein and resistance training.

How much protein should I eat on Ozempic or Wegovy? Most sports nutrition and clinical guidelines recommend 1.2–1.6 g of protein per kg of body weight per day during active weight loss. This is higher than typical dietary guidelines and requires intentional planning when appetite is suppressed.

Can I build muscle while on GLP-1? Building muscle in a significant caloric deficit is challenging. The realistic and clinically important goal on GLP-1 is to preserve lean mass while losing fat. True muscle gain (recomposition) may be more feasible once weight loss reaches maintenance phase.

Is muscle loss from GLP-1 permanent? No. Muscle lost during a caloric deficit can be regained through resistance training and adequate protein intake, particularly when the individual returns to a maintenance calorie level. The sooner protective habits are established, the less lost to begin with.

What is sarcopenic obesity and why does it matter for GLP-1 users? Sarcopenic obesity refers to having both excess fat mass and low muscle mass simultaneously. It is associated with worse metabolic outcomes than either condition alone. GLP-1 therapy that reduces fat without preserving muscle could inadvertently worsen the muscle component unless addressed proactively.

Ready to explore a medically supervised weight management programme that addresses muscle health alongside fat loss?

Learn more about Zoey's approach → zoey.sg

Zoey is a weight management programme designed for Singapore. Our clinical team combines GLP-1 therapy with personalised nutrition and lifestyle support to help you lose fat — and keep the muscle that matters.

References

• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989–1002. (STEP 1)
• Garvey WT, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nature Medicine. 2022;28:2083–2091.
• Conte C, et al. "Effects of GLP-1 receptor agonists on body composition and muscle mass: a systematic review." Obesity Reviews. 2024.
• Morton RW, et al. "A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength." British Journal of Sports Medicine. 2018;52(6):376–384.